newsfilter
← Latest News
Business Wire·

Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease

Jakafi XR is a once-daily, film-coated, extended-release formulation of Jakafi® (ruxolitinib) Once-daily Jakafi XR was shown to provide consistent, day-long exposure comparable to twice-daily Jakafi Jakafi